This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I wish to draw the attention of the readers of the ARCHIVES to issues relative to the safety of the medication alosetron hydrochloride, which is discussed in the recently published article.¹ Several weeks after resubmission of the revised manuscript to the journal and 8 days prior to its final acceptance for publication by the ARCHIVES, the manufacturer of alosetron (Lotronex; Glaxo Wellcome, Research Triangle Park, NC) decided to cease marketing the medication. This decision was taken after consultation with the Food and Drug Administration (FDA) about adverse effects that were attributable to use of the medication. The prevalence of constipation (25% with alosetron and 5% with placebo) and the proportion of patients who withdrew from the clinical trial because of constipation (10%) were clearly reported in the manuscript. There were no cases of ischemic colitis or hospitalizations or surgical procedures related to constipation in the cohort who participated in the . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chronic diarrhoea
Spiller
Gut 2007;56:1756-1757.
FULL TEXT